Author

Mustafa Erman

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

Thymic carcinoma (TC) is a rare and aggressive malignancy with limited evidence guiding second-line treatment after prior systemic therapy. We evaluated real-world outcomes of second-line systemic therapy in a multicenter cohort. Adults with unresectable, recurrent, or metastatic TC who received second-lin...

Fatih Kuş, Fatih Atalah, Gökhan Şahin et al. · BMC Cancer · 0 citations

Open access Sep 2026

Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis

Background/Objectives: Cabazitaxel is an established treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC), but outcomes beyond the conventional 10-cycle threshold remain incompletely characterized. This threshold largely reflects clinical trial design. We therefore evaluated outcom...

H. Taban, S. Aksoy, Y. Evlendi et al. · Journal of Clinical Medicine · 0 citations

Review Open access Sep 2026

Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study

Background and Objectives: Treatment-emergent neuroendocrine prostate cancer (t-NEPC) is an aggressive resistance phenotype arising during metastatic castration-resistant prostate cancer (mCRPC). Because metastatic biopsy is not routinely feasible in advanced disease, real-world data on clinically defined t-NEPC/aggres...

H. Taban, S. Aksoy, D. Güven et al. · Medicina · 0 citations